



A Carelon Company

**IMAAVY (NIPOCALIMAB)**

**ORDER SET**

**P: 877.365.5566 | F: 855.889.2946**

**PATIENT INFORMATION:**

Fax completed form, insurance information, and clinical documentation to 855.889.2946

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_

**Patient Status:** ☐ New to Therapy ☐ Continuing Therapy **Next Treatment Date:** \_\_\_\_\_

**MEDICAL INFORMATION**

**Diagnosis:** ☐ Myasthenia Gravis w/out acute exacerbation (ICD-10 Code: G70.00)  
☐ Myasthenia Gravis w/acute exacerbation (ICD-10: G70.01)  
☐ Other: \_\_\_\_\_ (ICD-10: \_\_\_\_\_)

**gMG Classification:** ☐ II ☐ III ☐ IV

Patient Weight: \_\_\_\_\_ lbs. (required) Allergies: \_\_\_\_\_

**THERAPY ORDER**

**Imaavy (nipocalimab-aahu)**

- (choose one)
- ☐ Initial Start:
    - Imaavy 30mg/kg IV x1 loading dose
    - Two weeks after loading dose administer maintenance dose of Imaavy 15mg/kg IV
    - Continue maintenance dose of Imaavy 15mg/kg IV every 2 weeks thereafter x 1 year
  - ☐ Maintenance Dose
    - Imaavy 15mg/kg IV every 2 weeks x1 year

Other orders: \_\_\_\_\_

**Lab Orders:** \_\_\_\_\_ **Frequency:** ☐ Every infusion ☐ Other: \_\_\_\_\_

Required labs to be drawn by: ☐ Paragon ☐ Referring Provider

Home IV Biologic Ana-kit Orders (adult):

- Epinephrine: >30kg (>66lbs): EpiPen 0.3mg or compounded syringe IM or subQ; may repeat in 5-10 minutes x1
- Diphenhydramine: Administer 25-50mg orally OR IV (adult)
- NS 0.9% 1000mL IV bolus per protocol PRN (adult)

Home biologic injection Ana-kit (adult):

- Dispense per protocol EpiPen 0.3mg IM (2-pack)

Flush orders: NS 1-20mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN

**PROVIDER INFORMATION**

By signing this form and utilizing our services, you are authorizing Paragon Healthcare, Inc. and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

Provider Name: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Provider NPI: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_

☐ Opt out of Paragon selecting site of care (if checked, please list site of care): \_\_\_\_\_

**PREFERRED LOCATION**

City: \_\_\_\_\_ State: \_\_\_\_\_

View our locations here:



PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



PHI-REF-ORD-10470-V1



A Carelon Company

## COMPREHENSIVE SUPPORT FOR IMAAVY (NIPOCALIMAB) THERAPY

### PATIENT INFORMATION:

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

### REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

- ☐ Include signed and completed order (MD/prescriber to complete page 1)
- ☐ Include patient demographic information and insurance information
- ☐ Include patient's current medication list
- ☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
  - ☐ Has the patient had a documented contraindication/intolerance or failed trial of conventional therapy (i.e., pyridostigmine, immunosuppressants, corticosteroids, or acetylcholinesterase inhibitors)? ☐ Yes ☐ No  
If yes, which drug(s)? \_\_\_\_\_
  - ☐ Has the patient required 2 or more courses of plasmapheresis/plasma exchanges and/or intravenous immune globulin for at least 12 months without symptom control? ☐ Yes ☐ No
  - ☐ Myasthenia Gravis Activities of Daily Living (MG-ADL) Score: \_\_\_\_\_
  - ☐ Does patient have a history of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation? ☐ Yes ☐ No
  - ☐ Does the patient have a history of positive anticholinesterase test? ☐ Yes ☐ No
- ☐ Include labs and/or test results to support diagnosis
  - ☐ anti-AChR antibodies OR anti-MuSK antibodies
- ☐ *If applicable* - Last known biological therapy: \_\_\_\_\_ and last date received: \_\_\_\_\_. If patient is switching biologic therapies, please perform a wash-out period of \_\_\_\_\_ weeks prior to starting nipocalimab.
- ☐ Other medical necessity: \_\_\_\_\_

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

**Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance**

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.